Economic evaluation of pharmacotherapy of migraine pain: a review of the literature.
This paper reviews the economic evaluation literature on pharmacotherapy for migraine and identifies important trends and gaps in the literature. Given the tremendous economic burden of migraine and the availability of various therapies for migraine treatment, economic evaluation of alternative therapies plays a critical role in identifying the most cost-effective therapy to optimize health care resource allocation and clinical decisions. Particularly, physicians and clinical administrators are expected to take an active role in resource allocation decisions at the clinical level. Thus, it is important for them to be familiar with the economic evaluation in migraine pain management, and most importantly, methodologies of economic analyses and the associated shortcomings of published estimates. In this paper, the methodological characteristics of these studies are examined and their results are compared and interpreted. Alternative treatment and health outcome measures are defined and data sources described while methods for assessing the direct and indirect costs are explored. Directions for future research are identified and discussed.
Yu
Junhua
J
Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah 84108, USA.
Goodman
Michael J
MJ
Oderda
Gary M
GM
D000700:Analgesics / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000379:methods*; D003661:Decision Support Techniques; D017048:Health Care Costs; D006801:Humans; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy*; D018803:Models, Economic; D010146:Pain / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome; D035501:Uncertainty
D000700:Analgesics